Valneva (NASDAQ:VALN) Sees Strong Trading Volume

Valneva SE (NASDAQ:VALN) saw unusually-strong trading volume on Friday . Approximately 4,092 shares were traded during trading, a decline of 61% from the previous session’s volume of 10,386 shares.The stock last traded at $7.37 and had previously closed at $7.35.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on VALN shares. Guggenheim lowered their price objective on shares of Valneva from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Valneva in a research report on Monday, June 24th.

Valneva Stock Performance

The company has a market cap of $527.16 million, a PE ratio of -18.34 and a beta of 2.20. The business’s 50-day moving average is $7.87 and its 200 day moving average is $8.11. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.22 and a current ratio of 2.64.

Valneva (NASDAQ:VALN) last issued its earnings results on Tuesday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.12. The company had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $95.80 million. Valneva had a negative net margin of 15.88% and a negative return on equity of 14.56%. On average, equities research analysts predict that Valneva SE will post -0.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

A hedge fund recently raised its stake in Valneva stock. General American Investors Co. Inc. raised its position in Valneva SE (NASDAQ:VALN) by 2.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 354,361 shares of the company’s stock after acquiring an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent quarter. 11.39% of the stock is owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.